Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03329378
Recruitment Status : Recruiting
First Posted : November 6, 2017
Last Update Posted : February 12, 2019
Sponsor:
Information provided by (Responsible Party):
Aarti S. Bhardwaj, Icahn School of Medicine at Mount Sinai

Brief Summary:

Primary Objective:

• Determination of pathologic complete response (pCR) rates

Secondary Objective:

  • Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain and troponin.
  • Breast conservation rates
  • Overall survival

Study Design

  • Approximately 34-74 patients with Her2 positive, Stage II-regional IV breast cancer will be enrolled.
  • Patients will be stratified by ER/PR status.
  • They will be randomized to ddACTHP vs TCHP.

    • Initially, 17 patients will be randomly assigned to each treatment arm.
    • If 3 or fewer patients have a pCR, then that arm will be terminated and no further patients will be entered on that treatment arm.
    • If 4 or more patients obtain a pCR, 20 additional patients (total of 37 patients) will be randomized to that treatment arm.
    • If 11 or more patients out of 37 have a pCR, the treatment will be of interest for further study.

Condition or disease Intervention/treatment Phase
Locally Advanced Breast Cancer Drug: Docetaxel Drug: Carboplatin Drug: Trastuzumab Drug: Pertuzumab Drug: Pegfilgrastim Drug: Paclitaxel Drug: Doxorubicin Drug: Cyclophosphamide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer
Estimated Study Start Date : February 1, 2019
Estimated Primary Completion Date : October 16, 2019
Estimated Study Completion Date : October 16, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: ddACTHP

Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Pegfilgrastim 6mg SC, day 2 of AC

Cycled every 14 days for 4 cycles, followed by, Paclitaxel 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15 Trastuzumab 8 mg/kg IV day 1, followed by 6mg/kg Pertuzumab loading dose 840 mg IV followed by 420 mg IV every 3 weeks

Cycled every 21 days for 4 cycles, followed by, Trastuzumab 6mg/kg every 21 days to complete 1 year

Drug: Pertuzumab
Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1

Drug: Trastuzumab
Trastuzumab 6mg/kg every 21 days to complete 1 year

Drug: Paclitaxel
Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.

Drug: Doxorubicin
Doxorubicin 60 mg/m2 IV day 1

Drug: Cyclophosphamide
Cyclophosphamide 600 mg/m2 IV day 1

Drug: Paclitaxel
80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15

Active Comparator: TCHP
TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim ) institutional practice is to titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
Drug: Docetaxel
Docetaxel 75mg/m2 IV, day 1

Drug: Carboplatin
Carboplatin AUC 6 IV, day 1

Drug: Trastuzumab
Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1

Drug: Pertuzumab
Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1

Drug: Pegfilgrastim
Pegfilgrastim 6mg SC, day 2 Cycled as per arm

Drug: Trastuzumab
Trastuzumab 6mg/kg every 21 days to complete 1 year

Drug: Paclitaxel
Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.




Primary Outcome Measures :
  1. pCR rates [ Time Frame: up to 2 years ]
    Pathologic complete response (pCR) defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of neoadjuvant systemic therapy.


Secondary Outcome Measures :
  1. Cardiac Toxicity [ Time Frame: up to 2 years ]

    Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain and troponin.

    Left ventricular ejection fraction (LVEF) measurement of amount of blood being pumped out of the left ventricle of the heart with each contraction.

    Peak systolic longitudinal strain is calculated by averaging the values of peak systolic strain in the basal, mid and apical segments of the LV in 4-, 3- and 2-chamber views on echocardiograms. A value of <-18% or a >15% decline in strain from patient's baseline value will be used as a cut-off value.

    A value of troponin I > 0.08 ng/ml 21, 30,31 will be considered elevated.


  2. Number of non-cardiac toxicities [ Time Frame: up to 2 years ]
    The frequency of adverse events categorized using CTCAE v4.03

  3. Breast Conservation Rates [ Time Frame: up to 2 years ]
    rate of breast-conserving surgery for patients for whom mastectomy was planned before treatment. It would be based on surgical opinion at time of surgery if the tumor was appropriately "downstaged" to perform breast conserving surgery on patients previously recommended to have a mastectomy.

  4. Overall Survival [ Time Frame: up to 2 years ]
    Overall Survival Rate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The patient must have signed and dated an IRB-approved consent form that conforms to federal and institutional guidelines.

  • Female
  • 18 years or older
  • ECOG performance status of 0 or 1
  • Eligible tumors must meet one of the following criteria:

    • Operable (T1c, T2-3, N0-1, M0)
    • Locally advanced (T2-3, N2-3, M0 or T4a-c, any N, M0)
    • Inflammatory breast cancer (T4d, any N, M0)
  • Staging evaluation:

    • History and physical exam, cbc, chemistry profile
    • CT Chest/Abdomen/Pelvis and a bone scan or PET/CT as needed
  • Diagnosis of invasive adenocarcinoma made by core needle biopsy
  • Breast cancer determined to be:
  • Confirmed HER2-positive : (ASCO CAP guidelines, 10/7/2013)

    • IHC 3+ based on circumferential membrane staining that is complete, intense
    • ISH positive based on:
    • Single probe average HER2 copy number ≥ 6 signals/cell
    • Dual probe HER2/CEP 17 ratio ≥ 2.0 with an average HER2 copy number ≥ 4.0 signals/cell
    • Dual probe HER2/CEP 17 ratio ≥ 2.0, with an average HER2 copy number of < 4.0 signals/cell
    • Dual probe HER2/CEP 17 ratio < 2.0 with the average HER2 copy number of ≥ 6.0 signals/cell
  • any ER or PR receptor status
  • LVEF assessment by echocardiogram within 30 days of initiation; EF of ≥ 55% considered normal.
  • Normal troponin I level at baseline
  • Blood counts must meet the following criteria:

    • ANC greater than or equal to 1500/mm3
    • Platelet count greater than or equal to 100,000/mm3
    • Hemoglobin greater than or equal to 10 g/dL
  • Serum creatinine less than or equal 2.5 mg/100ml
  • Adequate hepatic function by these criteria: total bilirubin must be less than or equal to 1.5 x the ULN for the lab unless the patient has a bilirubin elevation great than the ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and AST must be less than or equal to 1.5 x ULN for the lab. Both alkaline phosphatase and AST may not both be greater than the ULN.
  • Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET-CT or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements are met as above
  • Patients with alkaline phosphatase that is > ULN but less than or equal to 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease.

Exclusion Criteria:

Patients with a history of decompensated congestive heart failure or an EF < 55% will be excluded

• Cardiac disease that would preclude the use of the drugs included in the above regimens. This includes but is not confined to:

  • Active cardiac disease:
  • angina pectoris requiring the use of anti-anginal medication;
  • ventricular arrhythmias except for benign premature ventricular contractions controlled by medication;
  • conduction abnormality requiring a pacemaker;
  • supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; and
  • clinically significant valvular disease
  • symptomatic pericarditis
  • pulmonary hypertension
  • History of cardiac disease:
  • myocardial infarction;
  • congestive heart failure; or
  • cardiomyopathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03329378


Contacts
Layout table for location contacts
Contact: Neha Kumarley 212-824-7659 neha.kumarley@mssm.edu
Contact: Jalwa Afroz 212-824-7320 jalwa.afroz@mssm.edu

Locations
Layout table for location information
United States, New York
Mount Sinai Beth Israel Recruiting
New York, New York, United States, 10011
Contact: Damien Francois    212-604-6021    damien.francois@mssm.edu   
Contact: Tiffany Xing    212-604-6021    tiffany.xing@mountsinai.org   
Principal Investigator: Paula Klein, MD         
Mount Sinai West Recruiting
New York, New York, United States, 10019
Contact: Tahkir Mirzoyev, MD    212-523-7289    takhir.mirzoyev@mountsinai.org   
Principal Investigator: Anupama Goel, MD         
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Contact: Neha Kumarley    212-824-7659    neha.kumarley@mssm.edu   
Contact: Jalwa Afroz    212-824-7320    jalwa.afroz@mssm.edu   
Principal Investigator: Aarti Bhardwaj, MD         
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Investigators
Layout table for investigator information
Principal Investigator: Aarti Bhardwaj, MD Icahn School of Medicine at Mount Sinai

Layout table for additonal information
Responsible Party: Aarti S. Bhardwaj, Assistant Professor, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT03329378     History of Changes
Other Study ID Numbers: GCO 17-1585
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: February 12, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Aarti S. Bhardwaj, Icahn School of Medicine at Mount Sinai:
Neoadjuvant chemotherapy
locally advanced breast cancer
Her2neu

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Docetaxel
Albumin-Bound Paclitaxel
Cyclophosphamide
Carboplatin
Doxorubicin
Liposomal doxorubicin
Trastuzumab
Pertuzumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors